Abstract
Background
β‐Blockers are often withheld from patients with obstructive airways disease, especially those with reversible airways disease due to fear of inducing bronchospasm. We report our single center experience of cautiously treating such patients who have concomitant chronic heart failure (CHF).
Hypothesis
The use of cardioselective β‐blockers under caution and specialist supervision may be tolerable in many CHF patients with obstructive airways disease, resulting in clinical improvement rather than detriment.
Methods
A retrospective case notes analysis was performed on CHF outpatients who had obstructive airways disease and been treated with β‐blockers.
Results
A total of 43 patients were identified, with an average ejection fraction of 31.8%; 18 of these patients had fixed obstructive airways disease, 15 patients had reversible obstructive airways disease, 10 patients had a label of obstructive airways disease (but no supporting evidence for the diagnosis in the hospital notes). In all 3 groups, β‐blockers had been initiated and maintained without any respiratory event over a median continuous exposure time of 135 days. Limitation of the dose was documented in only 2 patients because of worsening shortness of breath. New York Heart Association (NYHA) class significantly improved for the group with the use of these agents (p = 0.003).
Conclusion
A cautious approach (under specialist supervision) to β‐blocker use in patients with heart failure and airways disease can result in successful treatment. The implications of withholding these agents may have more serious consequences than their administration. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (91.0 KB).
References
- 1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–823. [DOI] [PubMed] [Google Scholar]
- 2. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta‐adrenergic pathway. Circulation 1998; 98: 1329–1334. [DOI] [PubMed] [Google Scholar]
- 3. Nikolaidis LA, Hentosz T, Doverspike A, Huerbin R, Stolarski C. Catecholamine stimulation is associated with impaired myocardial O(2) utilization in heart failure. Cardiovasc Res 2002; 53: 392–404. [DOI] [PubMed] [Google Scholar]
- 4. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991; 325: 618–624. [DOI] [PubMed] [Google Scholar]
- 5. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–1355. [DOI] [PubMed] [Google Scholar]
- 6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet 1999; 353: 9–13. [PubMed] [Google Scholar]
- 7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet 1999; 353: 2001–2007. [PubMed] [Google Scholar]
- 8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194–2199. [DOI] [PubMed] [Google Scholar]
- 9. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225. [DOI] [PubMed] [Google Scholar]
- 10. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1–2. [DOI] [PubMed] [Google Scholar]
- 11. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under‐use of β‐blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98: 493–497. [DOI] [PubMed] [Google Scholar]
- 12. Stephen SA: Cardiac failure with propranolol. Br Med J 1968; 2: 428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Schwartz S, Davies S, Juers JA. Life‐threatening cold and exercise‐induced asthma potentiated by administration of propranolol. Chest 1980; 78: 100–101. [DOI] [PubMed] [Google Scholar]
- 14. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the β1‐selectivity of three β1‐selective β‐blockers. J Clin Pharm Ther 2003; 28: 179–186. [DOI] [PubMed] [Google Scholar]
- 15. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β‐blockers in patients with reactive airway disease: a meta‐analysis. Ann Intern Med 2002; 137: 715–725. [DOI] [PubMed] [Google Scholar]
- 16. Chupp GL. Say what, β‐blockers for asthma? Am J Respir Cell Mol Biol 2008; 38: 249–250. [DOI] [PubMed] [Google Scholar]
- 17. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C. Chronic exposure to β‐blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38: 256–262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Dickstein K, Cohen‐Solal A, Filippatos G, McMurray JJ, Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442. [DOI] [PubMed] [Google Scholar]